Table 2. Frequency of edema in phase II and III studies evaluating onartuzumab.
| Edema | ||||||
|---|---|---|---|---|---|---|
| Ona | Control | All grades, n (%) | Grade ≥3, n (%) | |||
| Study | n | n | Ona | Control | Ona | Control |
| GO27819 | 65 | 64 | 32 (49.2) | 11 (17.2) | 2 (3.1) | No events |
| GO27820 | 54 | 52 | 24 (44.4) | 1 (1.9) | 1 (1.9) | No events |
| GO27821 Bev Cohort (1) | 69 | 69 | 22 (31.9) | 4 (5.8) | 2 (2.9) | No events |
| GO27821 Pem Cohort (2) | 58 | 57 | 29 (50) | 10 (17.5) | 4 (6.9) | 1 (1.8) |
| GO27827 | 99 | 93 | 65 (65.7) | 12 (12.9) | 14 (14.1) | No events |
| OAM4861g Ona + Bev + Pac cohort* | 62 | 62* | 39 (62.9) | 13 (21.0)* | 5 (8.1) | No events* |
| OAM4861g Ona + Pbo + Pac cohort* | 58 | 62* | 37 (63.8) | As above* | 4 (6.9) | As above* |
| OAM4971g | 248 | 244 | 63 (25.4) | 23 (9.4) | 3 (1.2) | No events |
| YO28252 | 60 | 60 | 37 (61.7) | 10 (16.7) | 6 (10) | 2 (3.3) |
Bev = bevacizumab, Ona = onartuzumab, Pac = paclitaxel, Pbo = placebo, Pem = pemetrexed.
*Study OAM4861g had 3 arms: Ona + Bev + Pac (n = 62); Ona + Pbo + Pac (n = 58); Pbo + Bev + Pac (n = 62), referred to here as the control arm.